Genetic testing used to mean chasing one gene at a time. Today, whole exome sequencing changes the game by reading all the protein-coding instructions in your DNA in a single test. For families stuck in a years-long diagnostic odyssey, WES often provides the first clear answer.

This guide explains what whole exome sequencing is, how it works, when doctors recommend it, what it costs in India in 2026, and what its limits are — all in plain language.

What is whole exome sequencing?

Whole exome sequencing, also known as WES, is a genomic technique for sequencing all of the protein-coding regions of genes in a genome, known as the exome.

It consists of two steps: first select only the subset of DNA that encodes proteins. These regions are known as exons — humans have about 180,000 exons, constituting about 1% of the human genome, or approximately 30 million base pairs. The second step is to sequence the exonic DNA using any high-throughput DNA sequencing technology.

The goal is to identify genetic variants that alter protein sequences, and to do this at a much lower cost than whole-genome sequencing. Since these variants can be responsible for both Mendelian and common polygenic diseases, such as Alzheimer’s disease, whole exome sequencing has been applied both in academic research and as a clinical diagnostic.

In practice, WES looks at the 1–2% of your genome that makes proteins, where most known disease-causing mutations live.

Why WES matters for rare and undiagnosed disease

Exome sequencing is especially effective in the study of rare Mendelian diseases, because it is an efficient way to identify the genetic variants in all of an individual’s genes. These diseases are most often caused by very rare genetic variants that are only present in a tiny number of individuals.

Focusing on this 1% costs far less than whole genome sequencing but still detects a high yield of relevant variants.

Clinicians describe WES as striking a balance. Whole-exome sequencing facilitates the identification of individual nucleotide changes in protein-coding regions and flanking intronic regions of nearly all 20,000 genes in the human genome, to rapidly uncover rare disease-causing variants. In the evaluation of idiopathic disease, WES strikes a balance between cost, time of analysis, and scope of genetic information collected compared to more limited targeted gene panels.

Mayo Clinic Laboratories calls WES a first-line diagnostic tool for rare genetic disorders, noting it identifies 20,000 genes, detecting variants like single nucleotide changes and deletions, with high sensitivity and specificity.

How whole exome sequencing works: the two-step process

Step 1: Target enrichment

You cannot sequence just exons directly from blood or saliva. Labs first capture them.

Two main methods dominate:

• Array-based hybrid capture (2007 era): DNA fragments hybridize to oligos fixed on a microarray, then are washed and amplified
• In-solution capture (now standard): A pool of custom probes hybridizes in solution to fragmented DNA, beads pull down the regions of interest, and excess material is washed away

In-solution capture is preferred today because there is an excess of probes over template, giving excellent coverage of about 3.5 megabases of target.

Step 2: Next-generation sequencing

Captured exons are sequenced on short-read NGS platforms — Illumina NovaSeq, HiSeq, MiSeq, or similar instruments. These systems are particularly well suited to analyse many relatively short stretches of DNA sequence, as found in human exons.

A typical clinical WES generates 80–150x average coverage, meaning each base is read dozens of times to reduce errors.

WES vs other genetic tests

WES vs gene panels: Panels test 10–500 genes. They are cheaper but miss novel genes. WES surveys all 20,000.

WES vs microarray: Microarrays use hybridization probes to test known DNA sequences, thus they cannot identify unexpected genetic changes. WES directly provides nucleotide sequences at thousands of exonic loci.

WES vs whole genome sequencing (WGS): Exome sequencing is only able to identify those variants found in the coding region of genes which affect protein function. It is not able to identify the structural and non-coding variants associated with disease, which can be found using WGS. There remains 99% of the human genome that is not covered using exome sequencing, and exome sequencing allows sequencing of portions of the genome over at least 20 times as many samples compared to whole genome sequencing. The cost of exome sequencing is typically lower than whole genome sequencing.

Choose WES when you need a broad, cost-effective look at coding mutations. Choose WGS when you suspect deep intronic, mitochondrial, or complex structural variants.

Clinical applications where WES shines

1. Undiagnosed rare disease

A study analyzing 3,040 whole-exome sequencing cases found a 28.8% overall diagnostic yield, with 31% when analyzing three family members. Another large series found WES identified genetic defects in 25% of patients with suspected Mendelian disorders.

Diagnostic yields vary by phenotype:

• Hearing disorders: 55%
• Vision disorders: 47%
• Skeletal muscle disorders: 40%

In India-adjacent data, a Southeastern China study using WES found a 42.36% diagnostic rate for rare genetic diseases in children, outperforming singleton-WES.

2. Neurology and white matter disorders

Singleton WES achieved a first molecular diagnosis in 59% of genetic white matter disorder cases, rising to 68% after annual reanalysis.

3. Liver disease

Whole-exome and clinical-exome sequencing provided actionable diagnoses in 33% of idiopathic liver disease patients.

4. Autism spectrum disorder

In 50 children with ASD negative for copy number variations, WES found a 10% diagnostic yield.

5. Immunology and oncology

WES identifies cancer-related SNVs and CNVs, enabling PARP inhibitor and immunotherapy eligibility assessments. In primary immunodeficiencies, WES has proven an effective tool for discovery of genetic defects.

Overall, literature summarizes that WES identifies genetic causes in 25–40% of rare disease patients.

The trio advantage: patient plus parents

Most labs offer three formats:

• Proband-only: fastest, cheapest, yield ∼23–25%
• Trio (child + both parents): detects de novo variants, yield ∼31%
• Singleton with reanalysis: yield improves over time as databases grow

If budget allows, trio WES is recommended for neurodevelopmental disorders, because 83% of autosomal dominant alleles and 40% of X-linked alleles in one study were de novo.

What happens after sequencing: data analysis

Raw data is not a diagnosis. Bioinformatic pipelines align reads, call variants, and filter hundreds of thousands of candidates down to 1–3 reportable findings.

Key steps:

• Alignment to reference genome (BWA, DRAGEN)
• Variant calling (GATK)
• Annotation (population frequency, ClinVar, OMIM, HGMD)
• Phenotype-driven prioritization

Galaxy now dominates non-command-line WES processing, advancing clinical utility. Tools like ClinLabGeneticist integrate databases and automate reporting for clinical labs.

Challenges remain: false positive and false negative findings are associated with genomic resequencing approaches. Genetic heterogeneity and population ethnicity are also major limitations.

Benefits of whole exome sequencing

• Comprehensive: surveys all ∼20,000 genes at once
• Faster diagnosis: ends years of test-by-test hunting
• Cost-effective: balances scope and price versus panels and WGS
• Actionable: guides treatment, recurrence risk, family screening, and clinical trial eligibility
• Re-analyzable: data can be reinterpreted as new genes are discovered

Limitations you should know

• Misses 99% of non-coding genome, including deep intronic and regulatory variants
• Poor detection of large structural variants, repeat expansions, and mitochondrial heteroplasmy
• Coverage gaps in GC-rich regions
• Variants of uncertain significance (VUS) in 20–30% of cases
• Cannot detect epigenetic changes

That is why WES complements, not replaces, other tests like chromosomal microarray or WGS in complex cases.

Cost and accessibility in India (2026 update)

Genomic testing is rapidly becoming affordable. Even advanced procedures such as whole exome sequencing, earlier priced at around Rs 25,000, are now available at about Rs 18,000.

For comparison, whole genome sequencing is currently about Rs 60,000 and is expected to fall below Rs 20,000 in the next three years.

Major chains like Apollo, Agilus, Redcliffe, Metropolis, and Dr Lal PathLabs have expanded to Tier-2 and Tier-3 cities, driven by falling prices and rising physician adoption. India’s genomic diagnostics market stood at $550 million in 2024 and is projected to nearly triple to $1.5 billion by 2030.

Insurance coverage remains limited, so most families pay out-of-pocket. Always ask for pre-test counseling and a detailed quote that includes trio analysis and reanalysis policy.

Preparing for a WES test

1. Genetic counseling: review family history, prior tests, and consent
2. Sample collection: 2–5 ml blood in EDTA, or saliva kit
3. Turnaround: 4–8 weeks for clinical report
4. Results session: discuss pathogenic, likely pathogenic, VUS, and incidental findings
5. Follow-up: cascade testing for parents/siblings, referral to specialists

Ask your lab: What is the average coverage? Do you report secondary findings (ACMG 73 genes)? Is annual reanalysis included?

Ethical implications

With approaches such as exome sequencing, it is possible to significantly enhance the data generated from individual genomes which has put forth a series of questions on how to deal with the vast amount of information. Should the individuals in these studies be allowed to have access to their sequencing information? Should this information be shared with insurance companies?

In India, data privacy is governed by consent forms. Discuss:

• Storage of data and duration
• Sharing with research databases
• Right not to know incidental findings
• Psychological impact on family

Future directions

• Blended genome-exome: combines low-pass WGS with deep exome for cost parity with WES
• AI-driven interpretation: reduces VUS burden
• Long-read sequencing: improves detection of structural variants missed by short-read WES
• Population-specific databases: Indian genome databases will improve variant classification and reduce false positives

Frequently asked questions

What does whole exome sequencing test?
It sequences all protein-coding exons, about 1% of the genome, covering roughly 20,000 genes.

How is WES different from a genetic panel?
Panels look at a limited gene list. WES looks at all coding genes, increasing chance of finding novel or unexpected diagnoses.

What is the diagnostic rate?
Across studies, 25–40% for rare disease, with higher yields in trios and specific phenotypes like hearing loss.

How long does it take?
Sample to report typically 4–6 weeks, plus counseling.

Does WES detect everything?
No. It misses most non-coding variants, large rearrangements, and repeat expansions. WGS or other tests may be needed.

Is WES safe?
Yes, it is a blood or saliva test. Risks are informational, not physical.

Will my insurance cover it in India?
Coverage is limited in 2026. Check with insurer; many labs offer EMI options.

Can results change later?
Yes. Annual reanalysis can increase yield from 59% to 68% as knowledge grows.

Conclusion

Whole exome sequencing has moved from research labs to routine clinics because it answers the hardest question in medicine: why is this patient sick? By focusing on the 30 million base pairs that build proteins, WES delivers diagnoses in one-quarter to one-third of previously unsolved rare disease cases, at a price now under Rs 18,000 in India.

It is not perfect. It cannot see the whole genome, and interpretation requires expertise. But for children with developmental delay, adults with unexplained liver or neurologic disease, and families seeking recurrence risk, WES strikes the best balance of cost, time, and scope today.

If you are considering whole exome sequencing, start with genetic counseling, choose trio testing when possible, and pick a lab that offers transparent reporting and reanalysis. The exome may be only 1% of your genome, but for many families, it holds 100% of the answer.